Theratech and Proctor and Gamble partner in $35 million hormone replacement therapy deal:
This article was originally published in Clinica
Procter & Gamble and Theratech are to develop a combined transdermal testosterone and estradiol/testosterone hormone replacement therapy patch for women. P&G will fund the project and provide milestone payments up to $35 million to Theratech. P&G will retain marketing rights except in Asia, although certain Asian countries may be included in the deal. The testosterone patch is in Phase II trials.